At meeting held on 03 February 2021The Board of Solara Active Pharma Sciences at its meeting held on 03 February 2021 has approved the acquisition of additional share
capital in Sequent Penems (SPPL), subsidiary company of Solara.
Currently Solara holds 89.23% of SPPL and it is proposed to acquire remaining 10.77% to make it as a wholly owned subsidiary.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.